NO914541L - Fremgangsmaate ved fremstilling av tumor-nekrose-faktor-muteiner - Google Patents

Fremgangsmaate ved fremstilling av tumor-nekrose-faktor-muteiner

Info

Publication number
NO914541L
NO914541L NO91914541A NO914541A NO914541L NO 914541 L NO914541 L NO 914541L NO 91914541 A NO91914541 A NO 91914541A NO 914541 A NO914541 A NO 914541A NO 914541 L NO914541 L NO 914541L
Authority
NO
Norway
Prior art keywords
muteins
muteines
necrose
factor
procedure
Prior art date
Application number
NO91914541A
Other languages
English (en)
Other versions
NO914541D0 (no
Inventor
Walter Fiers
Jan Tavernier
Xaveer Van Ostade
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO914541D0 publication Critical patent/NO914541D0/no
Publication of NO914541L publication Critical patent/NO914541L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Human tumor-nekrose-faktor-mutein eller et far-masoytisk akseptabelt salt derav særpreget ved at TN F sekvensen er endret ved delesjon, innsetning og/eller substitusjon av én eller flere aminosyrer, slik at muteinet viser en signifikant forskjell mellom sin bindingsaffinitet for den humane ptumor-nekrose-faktor-reseptor, DNA sekvenser som koder for slike muteiner, vektorer omfattende slike DNA sekvenser, vertsceller transformert med slike vektorer, samt en fremgangsmåte for fremstilling av slike muteiner og som anvender slike transformerte vertsceller og farmasøytiske blandinger inneholdende slike muteiner samt deres bruk for behandlingen av lidelser, slik som kreft.
NO91914541A 1990-11-21 1991-11-20 Fremgangsmaate ved fremstilling av tumor-nekrose-faktor-muteiner NO914541L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP90810901 1990-11-21

Publications (2)

Publication Number Publication Date
NO914541D0 NO914541D0 (no) 1991-11-20
NO914541L true NO914541L (no) 1992-05-22

Family

ID=8205969

Family Applications (1)

Application Number Title Priority Date Filing Date
NO91914541A NO914541L (no) 1990-11-21 1991-11-20 Fremgangsmaate ved fremstilling av tumor-nekrose-faktor-muteiner

Country Status (17)

Country Link
US (2) US5422104A (no)
EP (1) EP0486908A3 (no)
JP (1) JPH06256395A (no)
AR (1) AR245783A1 (no)
AU (1) AU655948B2 (no)
CA (1) CA2055168A1 (no)
FI (1) FI915379A (no)
HU (1) HUT62034A (no)
IE (1) IE914035A1 (no)
IL (1) IL100062A0 (no)
MC (1) MC2300A1 (no)
MX (1) MX9102110A (no)
NO (1) NO914541L (no)
NZ (1) NZ240595A (no)
PT (1) PT99560A (no)
UY (1) UY23327A1 (no)
ZA (1) ZA919035B (no)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ283533B6 (cs) * 1992-04-02 1998-04-15 F. Hoffmann-La Roche Ag TNF - muteiny a způsob jejich výroby
CA2119089A1 (en) * 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
US7070771B1 (en) 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
CA2324138A1 (en) * 1998-03-20 1999-09-23 Charles A. Nicolette Novel complementing receptor-ligand pairs and adoptive immunotherapy using same
DE60028830T2 (de) * 2000-02-16 2007-01-18 Genentech, Inc., South San Francisco Anti-april antikörper und hybridomazellen
US7056695B2 (en) 2000-03-02 2006-06-06 Xencor TNF-α variants
US7101974B2 (en) 2000-03-02 2006-09-05 Xencor TNF-αvariants
US20070172449A1 (en) * 2000-03-02 2007-07-26 Xencor, Inc. TNF-alpha VARIANT FORMULATIONS FOR THE TREATMENT OF TNF-alpha RELATED DISORDERS
US7662367B2 (en) 2000-03-02 2010-02-16 Xencor, Inc. Pharmaceutical compositions for the treatment of TNF-α related disorders
US7244823B2 (en) 2000-03-02 2007-07-17 Xencor TNF-alpha variants proteins for the treatment of TNF-alpha related disorders
US7687461B2 (en) * 2000-03-02 2010-03-30 Xencor, Inc. Treatment of TNF-α related disorders with TNF-α variant proteins
US7446174B2 (en) 2001-03-02 2008-11-04 Xencor, Inc. Protein based TNF-α variants for the treatment of TNF-α related disorders
US6579522B1 (en) * 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
HUP0500992A3 (en) * 2001-08-03 2007-11-28 Genentech Inc Tacis and br3 polypeptides and uses thereof
US20030086903A1 (en) * 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
US7786282B2 (en) * 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US20050043516A1 (en) * 2002-07-25 2005-02-24 Genentech, Inc. TACI antibodies and uses thereof
WO2004050683A2 (en) * 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to tumor necrosis factor and uses thereof
ES2537738T3 (es) * 2003-06-05 2015-06-11 Genentech, Inc. Terapia de combinación para trastornos de células B
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
ES2340038T3 (es) * 2003-11-14 2010-05-28 Genvec, Inc. Composicion farmaceutica para tratar cancer de pancreas localmente avanzado (cpla) no extirpable.
TW201122103A (en) * 2004-01-06 2011-07-01 Hayashibara Biochem Lab Tnf antagonists and tnf inhibitors comprising the same as the active ingredient
EP1598075A1 (en) * 2004-05-21 2005-11-23 LEK Pharmaceuticals d.d. Process for the isolation and / or purification of proteins
GB0425972D0 (en) 2004-11-25 2004-12-29 Celltech R&D Ltd Biological products
CN101203247A (zh) * 2005-01-10 2008-06-18 研究发展基金会 用于癌症治疗的靶向嵌合分子
CA2629306A1 (en) * 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
WO2008127515A1 (en) * 2007-03-01 2008-10-23 Cytologic, Inc. Compositions and method for enhancing immune responses in mammals
WO2008124086A2 (en) * 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
US9605844B2 (en) * 2009-09-01 2017-03-28 Cree, Inc. Lighting device with heat dissipation elements
DK2953634T3 (da) 2013-02-07 2021-08-30 Massachusetts Gen Hospital Fremgangsmåder til udvidelse eller udtømning af regulerende t-celler
EP3139955B1 (en) 2014-04-30 2024-03-20 President and Fellows of Harvard College Fusion proteins for treating cancer and related methods
CA3043146C (en) 2016-11-09 2021-11-23 Philogen S.P.A. Il2 and tnf mutant immunoconjugates
CA3193273A1 (en) 2020-08-27 2022-03-03 Enosi Therapeutics Corporation Methods and compositions to treat autoimmune diseases and cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650674A (en) * 1984-07-05 1987-03-17 Genentech, Inc. Synergistic cytotoxic composition
GR851626B (no) * 1984-07-05 1985-11-26 Genentech Inc
DE3750056T2 (de) * 1986-06-20 1995-04-06 Dainippon Pharmaceutical Co Polypeptid-Mutanten des menschlichen TNF und für diese Mutanten codierende DNS.
JPH07106158B2 (ja) * 1986-12-04 1995-11-15 サントリー株式会社 抗腫瘍活性を有する新規ポリペプチドおよびその製造法
AU1346488A (en) * 1987-02-26 1988-09-26 Cetus Corporation Arginine-depleted human tumor necrosis factor
JPS63291590A (ja) * 1987-05-25 1988-11-29 Teijin Ltd 新規生理活性ポリペプチド
DE3843534A1 (de) * 1988-12-23 1990-07-12 Basf Ag Neue tnf-polypeptide

Also Published As

Publication number Publication date
FI915379A0 (fi) 1991-11-14
NZ240595A (en) 1994-09-27
CA2055168A1 (en) 1992-05-22
HUT62034A (en) 1993-03-29
EP0486908A2 (en) 1992-05-27
MX9102110A (es) 1992-07-08
HU913595D0 (en) 1992-01-28
AR245783A1 (es) 1994-02-28
IE914035A1 (en) 1992-06-03
EP0486908A3 (en) 1992-11-19
PT99560A (pt) 1992-10-30
AU655948B2 (en) 1995-01-19
IL100062A0 (en) 1992-08-18
US5422104A (en) 1995-06-06
AU8791591A (en) 1992-05-28
ZA919035B (en) 1992-08-26
FI915379A (fi) 1992-05-22
NO914541D0 (no) 1991-11-20
JPH06256395A (ja) 1994-09-13
US5652353A (en) 1997-07-29
UY23327A1 (es) 1992-05-19
MC2300A1 (fr) 1993-09-06

Similar Documents

Publication Publication Date Title
NO914541L (no) Fremgangsmaate ved fremstilling av tumor-nekrose-faktor-muteiner
NO931141L (no) Tnf-muteiner
DK75694A (da) Tumornecrosefaktor og derivater og mutantformer deraf, fremgangsmåde til fremstilling deraf, DNA som koder derfor, replicerbar udtrykkelsesvektor indeholdende DNA'en og celle transformeret dermed samt præparater omfattende tumornecrosefaktoren
GR3024263T3 (en) Methods and deoxyribonucleic acid for the preparation of tissue factor protein
DK209088D0 (da) Medicinpraeparater, deres fremstilling og anvendelse
CA2185352A1 (en) Novel muteins of ifn-.beta.
DK0382019T3 (da) Anvendelse af 5-methyltetrahydrofolsyre, af 5-formyltetrahydrofolsyre og af deres farmaceutisk acceptable salte til fremstilling af farmaceutiske præparater med reguleret frigivelse egnet til anvendelse ved terapi af depressive forstyrrelser, og således fremstillede farmaceutiske præparater
BR9907259A (pt) Compostos para terapia e diagnóstico de câncer de pulmão e processos para o seu uso
JO1365B1 (en) Laoxy repo nucleic polypeptide acid has a physiological activity on humans and includes a basic sequence for the coded arrangement of the said polypeptide and a method for producing this for polypeptide and the pharmacological composition included.
ATE194384T1 (de) Tnf-bindende proteine
DE69027865D1 (de) ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN
DK0572688T3 (da) Peptider, med organ-beskyttende aktivitet, fremgangsmåde til deres fremstilling og deres anvendelse ved terapi
NO915084L (no) Fremgangsmaate ved fremstilling av human interleukin-5 receptor
ATE187493T1 (de) Gp75 als tumorimpfstoff gegen melanome
DK0564461T3 (da) Anvendelse af antistoffer mod TNF eller fragmenter afledt deraf og xanthinderivater til kombinationsterapi samt præparater dertil
DK325289D0 (da) Strontiumsalt, fremgangsmaade til fremstilling heraf samt farmaceutiske midler indeholdende saltet
YU60199A (sh) Nove soli bpc peptida sa organo-zaštitnom aktivnošću, postupak za njihovo dobijanje i njihova primena u terapiji
DE68914397D1 (de) Menschliches Lymphotoxin.
SE8402199D0 (sv) Pharmazeutisches preparat enthaltend co-dergocrine und einen calcium-antagonisten
RU93005356A (ru) Tnf-мутеин
DK314587D0 (da) 1,4-dihydropyridinderivater, fremgangsmaade til deres fremstilling og laegemidler, der indeholder disse forbindelser
YU182791A (sh) Tnf-muteini
NO20005321L (no) Vertskodet protein uttrykt i Mareks sykdoms (MDV) infiserte celler og antistoffer til dette
Cioni et al. Transdifferentiation of larval Xenopus laevis iris under the influence of the pituitary
Wdzieczak-Bakala et al. Modulation of protein expression in murine bone marrow cells following in-vivo cytosine arabinoside treatment